Why Moderna, Inc. (MRNA) Surged Today

Yahoo

20-05-2025

We recently published a list of . In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA)stands against other stocks that stole the show today.
Ten mid-cap companies from diverse sectors stood out on Monday, outperforming the lackluster performance of major indices, thanks to a flurry of corporate developments that sparked investor appetite.
While the firms boasted between 5 and 14 percent gains, the Dow Jones rose by only 0.32 percent, while the S&P 500 and the tech-heavy Nasdaq each inched up by 0.09 percent and 0.02 percent, respectively.
In this article, we list the names of the top-performing stocks and detail the reasons behind their gains.
To come up with the list, we considered only the stocks with a $2 billion market capitalization and $5 million in trading volume.
A scientist surrounded by vials and beakers in a modern laboratory, proudly displaying a vaccine.
Moderna Inc. grew its share prices by 6.15 percent on Monday to finish at $26.39 apiece as investor sentiment was buoyed by the Department of Health and Human Services' pledge not to upend the US vaccine system.
Additionally, investors are in a wait-and-see mode for a planned 'massive framework' for the US vaccine industry.
Details have yet to be publicized, but the plan is being overseen by the Food and Drug Administration.
Investors were hopeful that any initiative could benefit both end-consumers and vaccine makers such as Moderna, Inc. (NASDAQ:MRNA), which found success with its own COVID-19 shots.
In the first quarter of the year, Moderna, Inc. (NASDAQ:MRNA) widened its net loss by 17.4 percent to $971 million from $1.17 billion in the same period last year. Revenues declined by 35 percent to $108 million from $167 million in the same period last year due to lower vaccination rates, coupled with the continued normalization of COVID into a seasonal commercial market.
Looking ahead, Moderna, Inc. (NASDAQ:MRNA) is targeting to book revenues between $1.5 billion and $2.5 billion.
Overall, MRNA ranks 8th on our list of stocks that stole the show today. While we acknowledge the potential of MRNA as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that has gone up since the beginning of 2025, while popular AI stocks have lost around 25%. If you are looking for an AI stock that is more promising than MRNA but that trades at less than 5 times its earnings, check out our report about this .
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.